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S UMMA R Y
S E T T I N G : In 2005, in response to the increasing
prevalence of rifampicin-resistant tuberculosis (RR-
TB) and poor treatment outcomes, Rwanda initiated
the programmatic management of RR-TB, including
expanded access to systematic rifampicin drug suscep-
tibility testing (DST) and standardised treatment.
OB J E C T I V E : To describe trends in diagnostic and
treatment delays and estimate their effect on RR-TB
mortality.
D E S I G N : Retrospective analysis of individual-level
data including 748 (85.4%) of 876 patients diagnosed
with RR-TB notified to the World Health Organization
between 1 July 2005 and 31 December 2016 in
Rwanda. Logistic regression was used to estimate the
effect of diagnostic and therapeutic delays on RR-TB
mortality.
R E SU LT S : Between 2006 and 2016, the median diag-
nostic delay significantly decreased from 88 days to 1
day, and the therapeutic delay from 76 days to 3 days.
Simultaneously, RR-TB mortality significantly de-
creased from 30.8% in 2006 to 6.9% in 2016. Total
delay in starting multidrug-resistant TB (MDR-TB)
treatment of more than 100 days was associated with
more than two-fold higher odds for dying. When delays
were long, empirical RR-TB treatment initiation was
associated with a lower mortality.
CONC LU S I ON : The reduction of diagnostic and treat-
ment delays reduced RR-TB mortality. We anticipate
that universal testing for RR-TB, short diagnostic and
therapeutic delays and effective standardised MDR-TB
treatment will further decrease RR-TB mortality in
Rwanda.
K E Y WORD S : TB; Rwanda; MDR-TB programmatic
management; MDR-TB diagnosis; MDR-TB treatment
RIFAMPICIN (RMP) is the most powerful anti-
tuberculosis drug, and resistance to RMP is a reliable
surrogate marker for multidrug-resistant tuberculosis
(MDR-TB), a major challenge for TB management
and control.1 Rapid diagnostic tools, such as Xpertw
MTB/RIF (Cepheid, Sunnyvale, CA, USA), have
greatly increased access to RMP drug susceptibility
testing (DST) and reduced diagnostic delay.2
Globally, the vast majority (75%) of new RMP-
resistant TB (RR-TB) patients remained undiagnosed
in 2017,3 fuelling RR-TB transmission.4 Logistical
challenges related to sample transport and result
reporting can cause diagnostic delays.5 Other chal-
lenges, such as the lack of decentralised RR-TB
treatment or access to RR-TB drugs, can cause
therapeutic delays in those already diagnosed. In
2017, the global RR-TB treatment success rate was a
mere 55%,3 with diagnostic and/or therapeutic
delays associated with poorer treatment outcome
and pre-treatment loss to follow-up (LTFU).2,6–13
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However, evidence on the effect of shortened delays
on RR-TB mortality is lacking.14
In Rwanda, the first patients with RR-TB were
documented in 1989 at the Kigali University Hospital,
Kigali, Rwanda. No standardised treatment regimen
was available and little could be offered to these
patients.15 In 2005, the programmatic management of
RR-TB (PMDT) was launched as a core component of
the National TB Control Programme (NTP).15 Coun-
trywide access to RR-TB testing and MDR-TB
treatment increased (Table 1). However, the effect of
increased access and shortened delays on RR-TB
mortality has never been investigated in Rwanda. We
therefore studied data from all RR-TB patients since
the start of PMDT in Rwanda—a study period of more
than 10 years in order 1) to describe trends in RR-TB
diagnosis and enrolment into MDR-TB treatment, 2)
to compare diagnostic and therapeutic delays between
different RMP DST methods and 3) to estimate the
association between shortened delays and RR-TB
mortality. To the best of our knowledge, this is the
first such nationwide population-based study.
METHODS
Design and study population
In this longitudinal retrospective analysis, we includ-
ed consecutive patients diagnosed with pulmonary
RR-TB who were registered between July 2005, when
the PMDT started, and December 2016.
Data collection
Patients were assigned a unique ID on treatment
initiation, or laboratory ID for those who did not
start treatment. Patient files were retrieved from their
respective health facilities. The National MDR-TB
register and the National Reference Laboratory
(NRL) registers were reviewed to extract relevant
data.
A standardised data collection tool (see Supple-
mentary Data) was used to capture demographics,
baseline clinical characteristics, type of RMP DST
used for diagnosis, dates of sample collection for
RMP DST, dates that RMP DST results were
available at the RR-TB testing laboratory, date of
MDR-TB treatment initiation, the programmatic
Table 1 Timeline showing changes to the programmatic management of MDR-TB in Rwanda
Period/year Intervention Implementation context
Before 2005 Passive surveillance of drug-resistant TB Selected patients’ samples (mostly those failing and relapsing from
the WHO Category 2 regimen) were shipped to collaborating
laboratory for DST, but no standard treatment for MDR/RR-TB
2005 Programmatic management of RR-TB and
systematic surveillance of drug-resistant TB
among retreated patients
The programmatic management of RR-TB (PMDT) was launched as
a core component of the NTP.15 PMDT comprised countrywide
surveillance of drug-resistant TB among previously treated TB
patients and the standardised long-duration MDR-TB regimen. As
the NRL’s capacity to perform DST was insufficient, patient
samples were shipped to external collaborating laboratories such
as the Institute of Tropical Medicine (Antwerp, Belgium), resulting
in long diagnostic delays26
2007 Strengthening RR-TB diagnostic capacity of the
NRL
The NRL introduced phenotypic DST using the proportion method
on Lo¨wenstein-Jensen medium (phenotypic)
2009 Strengthening RR-TB diagnostic capacity of the
NRL
The NRL introduced GenoTypeW MTBDRplus LPA (Hain Lifescience,
Nehren, Germany) for the rapid detection of MDR-TB
2012 Strengthening RR-TB diagnostic capacity at
referral laboratories
XpertW MTB/RIF (Cepheid, Sunnyvale, CA, USA) was piloted in six
referral hospitals
2013 Strengthening RR-TB diagnostic capacity at the
countrywide laboratory network
The logistics of sputum sample transportation (2/week motorbike
visits from each health centre to an Xpert site, and weekly sample
transportation from intermediate health facilities to connect with
LPA facilities) and timely reporting of results (phone call to a
dedicated NTP number in case of RR-TB results) strengthened this
diagnostic network.35 Moreover, reducing the diagnostic delay
and a high number of Xpert tests was rewarded through a
performance-based financing policy29
2014 Expending access to RR-TB rapid diagnostic Xpert testing was decentralised to the district hospital level and
became easily accessible to all 515 peripheral health facilities as
first-line diagnostics for all those aged 55 years and presumptive
TB patients with HIV coinfection, as well as all smear-positive TB
patients.15 The shorter MDR-TB treatment regimen was
introduced.36 All patients diagnosed with RR-TB were considered
eligible for the shorter MDR-TB regimen (previously only those
patients diagnosed with rifampicin and isoniazid resistance, i.e.,
MDR-TB, were eligible for the long regimen). Effective
coordination between diagnostic centres and the Rwandan health
facilities where TB care is provided was essential
MDR-TB¼multidrug-resistant TB; TB¼ tuberculosis; WHO¼World Health Organization; RR-TB¼ rifampicin-resistant TB; PMDT¼programmatic management of
drug resistant TB; NTP¼National Tuberculosis Control Programme; DST¼drug susceptibility testing; NRL¼national reference laboratory; LPA¼ line-probe assay;
HIV¼ human immunodeficiency virus.
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outcome (death before treatment initiation, death
during treatment, treatment success—cure or treat-
ment completion, treatment failure, treatment dis-
continuation and LTFU) and the outcome date.
Two trained MDR-TB experienced nurses collected
the data. They were supervised by the investigators.
Data were double-entered in a dedicated EpiData
database (EpiData Association, Odense, Denmark)
by two encoders. Discordances were resolved by
referring to the source.
Definition of variables
RR-TB diagnostic delay was defined as the number of
days between the date of collection of the first sputum
sample that led to RR-TB diagnosis and the date that
RMP DST results became available at the laboratory.
RR-TB therapeutic delay was defined as the number
of days between the date that RMP DST results
became available at the laboratory and the date that
MDR-TB treatment was started. Total RR-TB delay
was defined as the sum of RR-TB diagnostic delay
and RR-TB therapeutic delay.
A binary outcome ‘‘mortality’’ was constructed.
Patients were categorised as ‘‘dead’’ if they died before
or during MDR-TB treatment or as ‘‘survived
throughout treatment’’, after excluding those with
treatment failure or LTFU. In a sensitivity analysis,
patients with treatment failure or LTFU were
considered as dead (worst case scenario). It is
plausible that the majority of these patients with
MDR-/RR-TB and without (sufficient) treatment
died.
Data analysis
RR-TB incidence was calculated as an average of
cases registered in three recent years (2014, 2015 and
2016) divided by the estimated population size (2012
Demographic and Health Survey), and was expressed
per 100 000 population. The equality-of-medians test
was used to compare the median delays within
groups. RR-TB diagnostic delay and RR-TB thera-
peutic delay were categorised to facilitate logistic
regression. Univariate analysis was conducted for
each independent variable with mortality as the
outcome variable. To assess the effect of both types
of delay on mortality, adjusted for potential con-
founders, variables with P , 0.2 on univariate
analysis were included, together with both delay
variables in the multivariable logistic regression
analysis. Statistical significance was set at 0.05.
Kaplan–Meier techniques were used to estimate
survival. Follow-up time started on the date of the
first sputum sample collection that led to RR-TB
diagnosis, the outcome event was death. Patients who
survived throughout treatment were censored on the
date of treatment outcome. STATA v14.2 (Stata Corp,
College Station, TX, USA) was used for data analysis.
Ethics
The study protocol was approved by the Rwanda
National Ethical committee (RNEC), Kigali, Rwanda
(IRB 00001497 of IORG0001100; Ref No.0069/
RNEC/2017); the Institutional Review Board of the
Institute of Tropical Medicine, Antwerp, Belgium
(IRB/AB/AC/062; Ref No. 1208/17; 19/03/2018);
and the Ethics Committee of the Antwerp University
Hospital (UZA, Universitair Ziekenhuis Antwerpen
Ethische Commissie), Antwerp, Belgium (REG No.
B300201836458; 14/05/2018).
RESULTS
From 1 July 2005 to 31 December 2016, the Rwanda
NTP notified 876 patients with RR-TB. Of these, 787
(89.8%) had available records available (Table 2,
Figure 1), 730 (92.7%) of whom were included in the
primary RR-TB mortality analysis, while 39 (5.0%)
were excluded from any analysis and 18 were only
included in the sensitivity analysis.
Of the 730 eligible RR-TB patients, more were
male (57.5%) and the median age was 34 years
(interquartile range [IQR] 27–43). The human
immunodeficiency virus (HIV) co-infection status
was documented for 698 (95.6%), 291 (39.9%) of
whom were HIV co-infected (Table 2); this remained
stable over the study period (P ¼ 0.28, data not
shown). The majority of the patients (n ¼ 390,
53.7%) came from Kigali City, with an estimated RR-
TB incidence of 2.38 per 100 000 population per year,
with the lowest incidence in Northern Province (0.21/
100 000).
Of the 730 RR-TB patients, 49 (6.7%) died before
starting treatment (Table 3). In 611/681 (89.7%)
patients, treatment initiation was based on the RMP
DST result, while in 70 (10.3%), MDR-TB treatment
initiation was based on a presumptive RR-TB
diagnosis, most of whom (70/74, 94.6%) were
confirmed later. The majority (n ¼ 510, 74.9%) of
the patients were treated with the World Health
Organization (WHO) long regimen, and 171 (25.1%)
Table 2 RR-TB national notification vs. proportion sampled
Year
RR-TB notification
n
Sampled for the study
n (%)
2005 and 2006 90 67 (74.4)
2007 102 94 (92.2)
2008 74 73 (98.6)
2009 80 80 (100)
2010 91 86 (94.5)
2011 82 66 (80.5)
2012 57 53 (93.0)
2013 43 41 (95.3)
2014 82 73 (89.0)
2015 94 77 (81.9)
2016 81 77 (95.1)
Total 876 787 (89.8)
RR-TB¼ rifampicin-resistant tuberculosis.
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were treated with the shorter regimen,16,17 which was
introduced in mid-2014.
The history of TB treatment was known for 697
(95.5%) patients: 511 (73.3%) were previously
treated for TB and 186 (26.7%) were new TB
patients, 149 (80.1%) of whom had been diagnosed
since 2013. The ratio of new to previously treated TB
was 1.5:1 since 2013, a sharp increase from 0.09:1
before 2013. Among previously treated TB patients,
the majority (n ¼ 215, 79.6%) had failed the WHO
Category 2 treatment regimen before 2010, while
over half of patients (124, 51.5%) had failed
Category 1 (Figure 2) since 2010.
Among the 611 patients initiated on treatment
based on confirmed RR-TB, 228 (100%) were
initiated based on phenotypic DST before 2009,
which decreased to 3 (1.2%) after the implementa-
tion of line-probe assays (LPAs) and Xpert (Figure 3).
After the countrywide scale-up of Xpert testing in
2014, 170 (81.3%) patients were initiated based on
Xpert results and 39 (18.7%) based on LPA results,
and none based on phenotypic DST (Figure 3).
RR-TB diagnostic and treatment delays
The date of RR-TB diagnosis was available for 693/
730 patients, (Figure 1): the overall median diagnos-
tic delay was 58 days (IQR 6–85). Of these 693
patients, 82 were excluded from the therapeutic delay
analysis, as they died before starting treatment (n ¼
40) or started treatment before RR-TB confirmation
(n¼42) (Figure 1); the remaining 611 patients had an
overall median therapeutic delay of 8 days (IQR 4–
20).
The median diagnostic delay was significantly
longer for patients diagnosed using phenotypic DST
(median 87 days, IQR 78–98) compared to LPA
(median 40 days, IQR 25–55) or Xpert (median 1
day, IQR 0–3) (P , 0.01). The median therapeutic
delay was 2.6 times longer for patients who initiated
treatment based on phenotypic DST (median 21 days,
Figure 1 Flowchart showing inclusion and exclusion criteria for study participants. * Program-
matic outcome used in sensitivity analysis. † In sensitivity analysis, we assumed the worst outcome
(death) in these patients diagnosed with RR-TB, but without treatment or treatment failed.
‡ Includes patients who died before starting treatment (n ¼ 9) and 28 patients who started
treatment before RR-TB confirmation. RR-TB ¼ rifampicin-resistant tuberculosis; DST ¼ drug
susceptibility test; MDR-TB¼multidrug-resistant TB.
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IQR 9–53) compared to LPA (median 8 days, IQR 5–
13) and five times longer compared to Xpert (median
4 days, IQR 2–5) (P , 0.01) (Table 4).
The median diagnostic delay was significantly
longer (P , 0.01) in patients who died (median 80
days, IQR 34–96) than in patients who survived
throughout MDR-TB treatment (median 50 days,
IQR 5–84); however, the difference between the two
groups was not statistically significant (P ¼ 0.96)
(Table 4).
Female patients had slightly longer diagnostic
(median 67 days, IQR 11–86) and therapeutic
(median 9 days, IQR 5–23) delays than males
(median diagnostic delay 50 days, IQR 3–85 days;
median therapeutic delay 7 days, IQR 4–18),
although this was not statistically significant (P ¼
0.09 for diagnostic, and P ¼ 0.07 for therapeutic
delay) (Table 4).
Diagnostic and therapeutic delays were significant-
ly shorter among patients aged .54 years: respec-
tively 3 and 2 times shorter among those aged ,30
years. Diagnostic delay was shorter (P¼0.01) in HIV
co-infected patients (median 44 days, IQR 4–83) than
in HIV-negative patients (median 66 days, IQR 8–
86), although the difference was not statistically
significant (P¼ 0.33) (Table 4).
Patient treatment outcome and factors associated
with death
Of the 730 patients included in the overall mortality
analysis, 49 (6.7%) died before starting MDR-TB
treatment, while 63 (8.6%) died during treatment
(Table 3). Treatment was successful in 618 patients
(84.7%, 95% confidence interval [CI] 81.8–87.2),
457 (62.6%) of whom were declared cured and 161
(22.1%) completed MDR-TB treatment.
Before 2009 when a long RR-TB diagnostic delay
was the norm, mortality was significantly higher (P,
0.01) in patients for whom MDR-TB treatment
initiation had been based on available RMP DST
results (28.3%, 95%CI 21.9–35.4) than in those who
had been started on MDR-TB treatment before RR-
TB was confirmed (8.9%, 95%CI 2.3–21.2).
RR-TB-related mortality decreased significantly
from 30.8% (95%CI 19.9–43.4) in 2006 to 6.9%
(95%CI 2.3–15.5) in 2016 (Figure 4). In a multivar-
iable analysis, total delay of at least 100 days was
independently associated with mortality (adjusted
odds ratio [aOR] 2.45, 95%CI 1.35–4.46) (Table 5).
After including patients who failed treatment and
those lost to follow-up as dead, and those with
unknown status of HIV under the HIV-coinfected
category, and excluding all RR-TB diagnosed with
very low bacillary load (Mycobacterium tuberculosis,
n ¼ 31) using Xpert in sensitivity analyses, a total
delay of at least 100 days was still significantly
associated with mortality (respectively aOR 2.82,
95%CI 1.60–4.97), aOR 3.71 (95%CI 2.09–6.58)
and aOR 2.38 (95%CI 1.31–4.34) (Table 6).
HIV co-infection (aOR 2.27, 95%CI 1.35–3.82)
and age (.54 years; aOR 4.83, 95%CI 2.10–11.10)
remained associated with increased mortality (Table
5). Other variables such as sex, MDR-TB treatment
clinic and MDR-TB treatment regimen were not
significantly associated with mortality (Table 5).
Figure 5 shows that patients with a shorter diagnostic
delay and those who were HIV-negative were more
likely to survive (P, 0.001 and P¼0.01, respectively).
Table 3 Characteristics of RR-TB patients diagnosed between
2005 and 2016 in Rwanda, who were included in the analysis (n
¼ 730)
n (%)
Sex
Male 420 (57.5)
Female 310 (42.5)
Age, years
,30 252 (34.5)
30–44 307 (42.1)
45–54 96 (13.2)
.54 71 (9.7)
Unknown 4 (0.6)
Median [IQR] 34 [27–43]
Province
East 85 (11.6)
Kigali 390 (53.7)
North 36 (4.9)
South 144 (19.7)
West 72 (9.9)
Other country (Uganda) 3 (0.4)
HIV status
Negative 407 (55.7)
Positive 291 (39.9)
Unknown 32 (4.4)
TB treatment history
New 186 (25.5)
Previously treated* 511 (70.0)
Unknown 33 (4.5)
First RMP testing method
Phenotypic 347 (47.5)
LPA 199 (27.3)
Xpert 184 (25.2)
Treatment centre
Kabutare 563 (82.7)
Kibagabaga 71 (10.4)
Kibungo 47 (6.9)
MDR-TB treatment regimen
Long duration 510 (69.9)
Short course 171 (23.4)
Not treated† 49 (6.7)
Treatment outcome
Cured 457 (62.6)
Completed 161 (22.1)
Death during treatment 63 (8.6)
Death before treatment 49 (6.7)
* Previously treated patients includes WHO Category 1 failure (n ¼ 158,
30.9%), Category 2 failure (n¼ 262, 51.3%), Category 1 clinical relapse (n¼
51, 10%), Category 2 clinical relapse (n¼21, 4.1%), Category 1 defaulter (n¼
2, 0.4%), Category 2 defaulter (n¼6, 1.2%), MDR-TB treatment relapse (n¼
5, 1%), MDR-TB treatment failure (n¼ 1, 0.2%) and others (n¼ 5, 1%).
† Patients died before initiating treatment.
RR-TB ¼ rifampicin-resistant TB; IQR ¼ interquartile range; HIV ¼ human
immunodeficiency virus; RMP¼ rifampicin; LPA¼ line-probe assay; MDR-TB¼
multidrug-resistant TB; WHO¼World Health Organization.
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DISCUSSION
To the best of our knowledge, this is the first
nationwide RR-TB population-based study to show
that a shortened diagnostic delay is associated with a
decline in mortality. In Rwanda, RR-TB mortality
dropped from 30.8% in 2006 to 6.9% in 2016.
Mortality was more than two-fold higher in patients
with a total delay of 100 days than in those with a
delay of ,35 days. Delays in diagnosing and treating
RR-TB have been reduced through the nationwide
scale-up of rapid molecular RMP DST since 2014
(Table 1), when 100% of RR-TB patients were
diagnosed using molecular diagnostics, either Xpert
(81.3%) or LPA (18.7%).
Our study showed that MDR/RR-TB mortality
decreased as delays were reduced, mainly due to the
implementation of Xpert. This findings contrasts
with some previous studies which did not show an
effect of the use of Xpert on TB mortality.18,19 On the
other hand, our findings complement those from a
Peruvian study conducted in patients already started
Figure 2 Proportion of patients with RR-TB based on their history of TB treatment by year of diagnosis. RR-TB¼ rifampicin-resistant
tuberculosis; MDR-TB¼multidrug-resistant TB.
Figure 3 Diagnosis of RR-TB by type of RR-TB DST and year of diagnosis among patients with confirmed RR-TB (n¼ 611) before
MDR-TB initiation. RR-TB¼ rifampicin-resistant tuberculosis; DST¼ drug susceptibility test; LPA¼ line-probe assay.
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on MDR-TB treatment, which showed a decreased
odds (0.5) of death and increased odds (1.4) of
treatment success associated with the implementation
of rapid phenotypic (microscopic-observation drug
susceptibility) and genotypic (LPA) DST.13
Consistent with findings from other studies,13 HIV
coinfection and older age were associated with
mortality, although HIV-coinfected and older pa-
tients were diagnosed more rapidly than HIV-
negative and younger patients.
Table 4 RR-TB diagnostic and treatment delay
RR-TB diagnostic delay
(n ¼ 693)*
(days)
RR-TB treatment delay
(n ¼ 611)†
(days)
Patients
n Median IQR P value
Patients
n Median IQR P value
Sex Male 406 50 3–85 0.09 356 7 4–18 0.07
Female 287 67 11–86 255 9 5–23
Age, years‡ ,30 236 74 16–91 Reference 211 11 6–30 Reference
30–44 290 53 5–83 0.07 255 8 4–17 0.02
45–54 94 61 4–80 0.27 83 7 3–15 0.03
.54 70 24 1–78 0.02 62 5 2–9 ,0.01
Province§ Kigali 245 26 2–74 Reference 224 7 4–13 Reference
East 70 13 1–63 0.81 67 4 2–9 0.03
North 23 39 1–57 0.27 23 5 2–11 0.46
South 104 34 2–62 0.33 101 7 3–9 0.90
West 52 31 3–77 0.70 52 7 3–12 0.94
HIV¶ Negative 392 66 8–86 0.01 364 8 4–22 0.33
Positive 277 44 4–83 246 7 4–17
DST confirming
RR-TB
Phenotypic 313 87 78–98 Reference 241 21 9–53 Reference
LPA 197 40 25–55 ,0.01 187 8 5–13 ,0.01
Xpert 183 1 0–3 ,0.01 183 4 2–5 ,0.01
Survival Survived# 591 50 5–84 ,0.01 556 8 4–19 0.96
Died 102 80 34–96 55 8 3–26
*Days between sample collection and rifampicin DST result available at RR-TB testing laboratory.
† Days between rifampicin resistance diagnosis available at RR-TB testing laboratory and start of RR-TB appropriate
treatment.
‡ Patients without age information were not categorised.
§ Patients diagnosed and initiated on MDR-TB treatment since 2009 onward.
¶ Patients with unknown HIV coinfection status were not included.
# Patients who were reported as cured and those completed treatment.
RR-TB ¼ rifampicin-resistant TB; IQR ¼ interquartile range; HIV ¼ human immunodeficiency virus; DST ¼ drug
susceptibility testing; LPA¼ line-probe assay; MDR-TB¼multidrug-resistant TB.
Figure 4 RR-TB diagnostic delay and total delay in initiating MDR-TB (time in days between the date of sample collection that led to
diagnosis of rifampicin resistance and date of MDR-TB treatment initiation) and mortality recorded by year of diagnosis. RR-TB ¼
rifampicin-resistant tuberculosis; MDR-TB¼multidrug-resistant TB.
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Although the clinical decision to start MDR-TB
treatment before laboratory confirmation is challeng-
ing, it resulted in a lower mortality during the period
that rapid molecular DST was not available and when
diagnostic delays were very long.7 This should not be
surprising. In patients with multiple risk factors, a
susceptible RMP DST result is unlikely to lower the
post-test probability below the treatment threshold, the
minimal level of probability of having RR-TB that is
required to start MDR-TB treatment.20 Hence, empir-
ical RR-TB treatment seems justified in such situations,
especially when an effective treatment is available and
when delay is associated with mortality.21
In our study, the treatment success rate was
relatively high (84.7%).13 The high rate of treatment
success is in line with low rates of resistance to
second-line drugs such as fluoroquinolones22,23 and
second-line injectables. None of the over 400 RR-TB
Table 5 Factors associated with RR-TB mortality
Total
n
Death*
n (%)
Univariate analyses Multivariable analyses
OR (95% CI) aOR (95% CI)†
Total 730 112 (15.3)
Sex
Female 310 41 (13.2) Reference Reference
Male 420 71 (16.9) 1.33 (0.88–2.02) 1.57 (0.93–2.62)
Age, years
,30 252 22 (8.7) Reference Reference
30–44 311 59 (19.0) 2.45 (1.45–4.12) 2.11 (1.08–4.12)
45–54 96 15 (15.6) 1.94 (0.96–3.91) 2.20 (0.95–5.08)
.54 71 16 (22.5) 3.04 (1.50–6.17) 4.83 (2.10–11.10)
HIV
Negative 407 34 (8.4) Reference Reference
Positive 291 47 (16.2) 2.11 (1.32–3.38) 2.27 (1.35–3.82)
Unknown 32 31 (96.9)
RR-TB total delay, days‡
1–34 232 23 (9.9) Reference Reference
35–99 235 29 (12.3) 1.28 (0.72–2.28) 1.28 (0.68–2.44)
At least 100 226 50 (22.1) 2.58 (1.51–4.40) 2.45 (1.35–4.46)
Unknown 37 10 (27.0)
MDR-TB treatment clinics
Kibagabaga 71 5 (7.0) Reference
Kibungo 47 4 (8.5) 1.23 (0.31–4.83)
Kabutare 563 54 (9.6) 1.40 (0.31–4.83)
Not treated 49 49 (100)
MDR-TB treatment regimen
Short course 510 14 (8.2) Reference
Long duration 171 49 (9.6) 1.19 (0.64–2.22)
Not treated 49 49 (100)
*A total number of 112 persons died. Data were missing for some explanatory variables: total delay was missing for 37
patients, age was missing for 4 patients (imputed median age was used), HIV status was not known for 31 patients and
for 49 no MDR-TB treatment regimen and clinic was assigned, as they died before starting treatment. For patients
missing therapeutic delay, imputed values based on patients’ age, sex, HIV coinfection and diagnostic delay were used.
† Adjusted for age, sex and HIV co-infection.
‡ Sum of time (in days) between sample collection and rifampicin susceptibility test result availability at testing
laboratory and time (in days) between rifampicin resistance diagnosis availability at testing laboratory and start of
appropriate RR-TB treatment.
RR-TB¼ rifampicin-resistant tuberculosis; OR¼ odd ratio; CI¼ confidence interval; aOR¼ adjusted OR; HIV¼ human
immunodeficiency virus; MDR-TB¼multidrug-resistant TB.
Table 6 Sensitivity analysis for factors associated with RR-TB mortality
Total RR-TB delay, days§ aOR (95% CI)* aOR (95% CI)† aOR (95% CI)‡
1–34 Reference Reference Reference
35–99 1.31 (0.71–2.40) 1.73 (0.93–3.18) 1.13 (0.58–2.18)
At least 100 2.82 (1.60–4.97) 3.71 (2.09–6.58) 2.38 (1.31–4.34)
§ Sum of days between sample collection and RR-TB DST result available at testing laboratory and days between
rifampicin resistance diagnosis available at testing laboratory and start of RR-TB appropriate treatment.
*Considering patients who failed treatment and those lost to follow-up as dead, adjusted for age, sex and HIV co-
infection when lost to follow-up and failure on MDR-TB treatment were considered dead.
† Considering those with unknown status of HIV as HIV-coinfected, adjusted for age, sex and HIV co-infection when
patients with unknown HIV coinfection status are considered as HIV-positive.
‡ Excluding all RR-TB identified diagnosed on Xpert with very low bacillary load (very low M. tuberculosis, n ¼ 31),
adjusted for age, sex and HIV co-infection excluding patients diagnosed on Xpert with TB very low (high likelihood of
being false RR-TB).
RR-TB¼ rifampicin-resistant TB; aOR¼ adjusted odd ratio; CI¼ confidence interval; HIV¼ human immunodeficiency
virus; MDR-TB¼multidrug-resistant TB.
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patients routinely tested since 2010 displayed resis-
tance to these drugs (NRL Rwanda, unpublished
findings), confirming that the standardised MDR-TB
treatment used was effective in curing RR-TB and
halting its spread. In fact, before the implementation
of PMDT in Rwanda, the estimated prevalence of
RR-TB among new TB patients rose from 1.3%
(95%CI 0.7–2.1) in 1993 to 3.9% (95%CI 2.5–5.7)
in 2005,24,25 likely fuelled by ongoing transmission.26
Before RR-TB testing became easily accessible, the
majority of the RR-TB patients diagnosed before
2013 had a primary RR-TB strain, but received
multiple rounds of ineffective RMP-based treatment,
while spreading RR-TB in their communities. This
probably explains the increase of RR-TB prevalence
among new TB patients, as shown in 2005.25 Since
the implementation of PMDT, drug resistance surveys
revealed a statistically significant decline in RR-TB
prevalence among new TB patients, from 3.9%
(95%CI 2.5–5.7) in 2005 to 1.4% (95%CI 0.7–2.1)
in 2015.25,27 Thus, the combination of early RR-TB
diagnosis with effective MDR-TB treatment likely
reduced transmission and probably explains the
decrease in RR-TB prevalence, as observed in the
2015 survey.27
Nonetheless, the programme should be cautious of
sole dependence on rapid molecular testing because
1) a shortage of reagents (e.g., cartridges) could
Figure 5 Kaplan-Meier survival estimates in patients with rifampicin-resistant tuberculosis by A)
diagnostic delay, and B) HIV coinfection. HIV¼ human immunodeficiency virus.
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completely paralyse the diagnostic system,28,29 2) the
increased sensitivity of the newly developed Xpertw
MTB/RIF Ultra (Cepheid) may complicate its use in
detecting true treatment failures or relapses, as
persistent DNA may not reflect active disease,30 3)
commercial rapid molecular diagnostics miss RMP
resistance-conferring mutations outside the 81 base
pair RMP resistance-determining region (RRDR),
such as Val170Phe and Ile491Phe,31,32 and 4) false-
positive RR-TB results on Xpert may be associated
with low bacillary load in the sample.33 However, a
sensitivity analysis which excluded all RR-TB iden-
tified using Xpert with very low bacillary load did not
affect the interpretation of the final model.
Our study had several important strengths. First,
85.4% of all patients diagnosed with RR-TB in
Rwanda over a period of more than 10 years were
included in the study. Our findings thus represent the
current reality of the MDR/RR-TB programme in
Rwanda. Second, in contrast with most studies on
RR-TB outcomes, data from patients who died before
starting treatment were included. Survival bias was
therefore limited. Third, we validated data by
comparing data collected from different sources
(patient files, the national MDR-TB register and
NRL registers). When discrepancies were identified,
sources were consulted a second time. Finally, a
sensitivity analysis including those who failed treat-
ment or were lost to follow-up, was used to confirm
the findings of the primary analysis.
Our study also had some important limitations. We
did not collect data on the delay between the day a
patient became at risk for MDR-/RR-TB and the date
RMP DST was requested. In addition, we did not
collect data on the severity of TB disease, such as
extensiveness of TB on X-ray, the bacterial load in
diagnostics or patient body mass index. Moreover,
second-line drug susceptibility was not tested system-
atically and could not be taken into account.
However, it should be noted that resistance to
second-line drugs is extremely rare in Rwanda.
Another important limitation was the lack of
systematic data on timing of antiretroviral therapy
initiation. The strong association between HIV-
coinfection and RR-TB mortality could thus not be
explored further. Finally, as this was a retrospective
study, we could only adjust for those variables that
were routinely collected.
In conclusion, diagnostic and treatment delays
were strongly associated with RR-TB mortality in
Rwanda. As the NTP were able to control delays,
mortality declined from 30.8% in 2006 to 6.9% in
2016. Other factors that likely contributed to
improved MDR-/RR-TB outcomes were universal
RMP resistance surveillance enhanced by perfor-
mance-based financing and the implementation of
effective standardised MDR-TB treatment. We antic-
ipate that universal testing of all TB patients for RR-
TB, short diagnostic and therapeutic delays, and
effective MDR-TB treatment will further reduce RR-
TB prevalence in Rwanda.
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R E´ S U M E´
CONT EX T E : En 2005, en re´ponse a` une pre´valence
croissante de la tuberculose re´sistante a` la rifampicine
(RR-TB) et aux re´sultats me´diocres du traitement, le
Rwanda a initie´ la gestion programmatique de la RR-
TB, notamment l’expansion de l’acce`s syste´matique au
test de pharmacosensibilite´ de la rifampicine et au
traitement standardise´.
O B J E C T I F : De´crire les tendances du retard au
diagnostic et au traitement et estimer leur impact sur la
mortalite´ de la RR-TB.
S C H E´ M A : Une analyse re´trospective de donne´es
individuelles de 748 (85,4%) patients sur 876 ayant eu
un diagnostic de RR-TB de´clare´e a` l’Organisation
mondiale de la Sante´ entre le 1er juillet 2005 et le 31
de´cembre 2016 au Rwanda. La re´gression logistique a
e´te´ utilise´e pour estimer l’impact du retard au diagnostic
et au traitement sur la mortalite´ de la RR-TB.
R E´ S U LTAT S : Entre 2006 et 2016, le de´lai me´dian du
diagnostic a significativement diminue´ de 88 jours a` 1
jour et le de´lai de traitement, de 76 jours a` 3 jours.
Paralle`lement, la mortalite´ lie´e a` la RR-TB a
significativement diminue´ de 30,8% en 2006 a` 6,9%
en 2016. Un retard de traitement de la TB
multire´sistante (MDR-TB) de plus de 100 jours a e´te´
associe´ a` un risque plus de deux fois supe´rieur de de´ce`s.
Quand les de´lais ont e´te´ longs, la mise en œuvre d’un
traitement empirique de la RR-TB a e´te´ associe´e a` une
diminution de la mortalite´.
CONC LU S I ON : La diminution du retard au diagnostic
et au traitement a re´duit la mortalite´ de la RR-TB. Nous
nous attendons a` ce que le test syste´matique de RR-TB,
un de´lai court de diagnostic et de traitement et un
traitement standardise´ efficace de la MDR-TB diminue
encore la mortalite´ de la RR-TB.
R E S UM E N
MARCO DE R E F E R ENC I A: En el 2005, en respuesta a un
aumento en la prevalencia de la tuberculosis resistente a
rifampicina (RR-TB) y los desenlaces terape´uticos
desfavorables, se inicio´ en Rwanda el manejo
programa´tico de la RR-TB, que incluı´a la expansio´n
del acceso a las pruebas sistema´ticas de sensibilidad a
rifampicina y al tratamiento normalizado.
OB J E T I VO: Describir las tendencias del retraso en el
diagno´stico y el tratamiento y analizar su efecto sobre la
mortalidad por RR-TB.
M E´ TODO: Se realizo´ un ana´lisis retrospectivo de los
datos individuales de 748 de los 876 pacientes (85,4%)
con diagno´stico de RR-TB notificados a la Organizacio´n
Mundial de la Salud entre el 18 de enero del 2005 y el 31
de diciembre del 2016 en Rwanda. Mediante regresio´n
logı´stica se calculo´ el efecto del retraso en el diagno´stico
y el tratamiento sobre la mortalidad por RR-TB.
R E SU LTADOS: Del 2006 al 2016, la mediana del retraso
diagno´stico disminuyo´ de manera considerable de 88
dı´as a un dı´a y la mediana del retraso terape´utico paso´ de
76 a 3 dı´as. De manera simulta´nea, se observo´ una
importante disminucio´n de la mortalidad por RR-TB, de
30,8% en el 2006 a 6,9% en el 2016. Un retraso total del
comienzo del tratamiento de la tuberculosis
multirresistente (MDR-TB) superior a 100 dı´as se
asocio´ con una posibilidad de mortalidad superior al
doble. Donde los retrasos eran prolongados, el comienzo
empı´rico del tratamiento contra la RR-TB se asocio´ con
una menor mortalidad.
CONC LU S I O´ N: La disminucio´n de los retrasos en el
diagno´stico y el tratamiento disminuyo´ la mortalidad
por RR-TB. Se propone que la realizacio´n de la prueba
de resistencia a rifampicina a todos los pacientes, un
corto lapso hasta el diagno´stico y el comienzo del
tratamiento y un tratamiento eficaz normalizado de la
MDR-TB disminuira´n au´n ma´s la mortalidad por RR-
TB en Rwanda.
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